Figure 1
From: CD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritis
Ps and PsA patients have a higher percentage of CD14+CD16+ cells. Human peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood, stained with an antibody cocktail composed of CD14-APC, CD16-PE, 7AAD, and analyzed by flow cytometry. Dead cells were excluded by 7AAD+. (a) Classical (CD14+CD16-, red line) and non-classical (CD14+CD16+, blue line) monocytes were labeled based on the classification by Strauss-Ayali and colleagues [5]. (b) The percentage of CD14+CD16+ cells in the PBMC of 16 healthy controls (HC), and 29 psoriasis (Ps), 28 psoriatic arthritis (PsA), and 8 rheumatoid arthritis (RA) patients. (c) The percentage of CD14+CD16+ cells in enriched human monocytes from HC and PsA. Monocytes were enriched by the Human Monocyte Enrichment Cocktail. The percentage of CD14+CD16+ cells in enriched monocytes from HC (2.6 ± 1.6%) and PsA patients (10.3 ± 9.5%) are shown in [a] and [b], respectively. The data are representative of 10 independent experiments.